-Industry Leader in Ophthalmic Drug Development-
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 22, 2015--
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the
appointment of ophthalmic drug development expert, Cadmus Collins Rich,
MD, MBA, CPE, as Vice President, Medical Affairs and Clinical
Development. Most recently, Dr. Rich served as a Therapeutic Unit Head
at Alcon for intraocular lenses. Prior to this he was the Global Head,
Pharmaceutical Clinical Trial Management at Alcon, where he led a team
of 25-plus MDs and PhDs and shepherded the submission and approval of
Nevanac®, Durezol®, and Izba®, and the
recently approved glaucoma treatment, Simbrinza®. In his
role, Dr. Rich will report to Rudolf Baumgartner, M.D, Chief Medical
Officer of Inotek.
“We are pleased to welcome Dr. Rich to Inotek. He brings to the company
a wealth of experience as a practicing ophthalmologist and as a seasoned
clinical developer focused on ophthalmology having worked both in
Specialty Pharma and in a Contract Research Organization,” said Dr.
Rudolf Baumgartner, Chief Medical Officer. “Dr. Rich’s clinical
development experience will be important to us as we progress
trabodenoson through clinical trials, and build our portfolio. We will
also benefit from his years as a practicing ophthalmologist and the
respect he has earned among a network of medical and scientific
specialists focused on ophthalmology. We look forward to his
contributions as we grow our company and advance trabodenoson towards an
NDA.”
Prior to Alcon, Dr. Rich served as Senior Director in the Integrated
Patient and Site Strategies Group, Global Head of Pathways and North
American Head of Prime Sites at Quintiles Translational, where he
developed a new business unit in ophthalmology that he grew into a
Center of Excellence. Other past industry experience includes serving as
Medical Director at AAI Pharma and Managing Director and Medical
Director at the American Institute of Healthcare and Fitness. As a
physician, Dr. Rich was an ophthalmologist and principal investigator at
North Carolina Eye, Ear, Nose and Throat and served on the Board of
Directors at N.C. Specialty Hospital in Durham, N.C. He received his BA
in psychology from Case Western Reserve University, MBA with honors from
Regis University and MD from the University of North Carolina School of
Medicine. Dr. Rich completed his Transitional Internship at Carilion
Health Systems in Roanoke, VA and his Ophthalmology Residency at the
University of North Carolina School of Medicine/UNC Hospitals in Chapel
Hill, NC. Dr. Rich is a Board Certified ophthalmologist, a Fellow of the
American Academy of Ophthalmology and a Certified Physician Executive.
“I am excited to be a part of the Inotek team, and to be able to help
the company deliver on the potential of trabodenoson and expand the
portfolio,” said Dr. Rich. “We believe the non-clinical and clinical
data to date describe a novel mechanism of action with a favorable
benefit-risk profile that will meet a significant unmet medical need of
patients with ocular hypertension and glaucoma.”
About Inotek Pharmaceuticals
Inotek Pharmaceuticals is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies for glaucoma and other
eye diseases. Our lead product candidate, trabodenoson, is a
first-in-class selective adenosine mimetic developed in Inotek’s
laboratories designed to restore the eye’s natural pressure control
mechanism. The development of trabodenoson monotherapy delivered in a
once-daily eye drop formulation will be followed by a fixed-dose
combination of trabodenoson with latanoprost. Additionally, we are
evaluating the potential for selective adenosine mimetics to address
optic neuropathies and other degenerative retinal diseases.
Nevanac®, Durezol®, Izba®, and Simbrinza®
are registered trademarks of Novartis AG.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. These statements often include words such
as "believe," "expect," "anticipate," "intend," "plan," "estimate,"
"seek," "will," "may" or similar expressions. Accordingly, you should
not place undue reliance on these forward-looking statements. All such
statements speak only as of the date made, and the Company undertakes no
obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150722005272/en/
Source: Inotek Pharmaceuticals Corporation
Inotek Contact:
Claudine Prowse, Ph.D., 781-552-4305
Vice
President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com
or
Media
Contact:
MacDougall Biomedical
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
